Roche and Novo-backed Corvus Pharmaceuticals priced its IPO at the lower end of its range and raised $70.5m when it floated on Nasdaq yesterday.
US-based cancer treatment developer Corvus Pharmaceuticals, backed by pharmaceutical companies Novo and Roche, floated on Nasdaq yesterday, having priced 4.7 million shares at $15 each, securing $70.5m in proceeds.
The pricing is at the lower end of Corvus’ target range, set between $15 and $17 set last week. That range already represented a reduction from the $115m initial public offering that the company originally filed for in January 2016.
Founded in 2014, Corvus is working on immune-oncological therapies…
